Goldman Sachs
RXRX icon

Goldman Sachs’s Recursion Pharmaceuticals RXRX Stock Holding History

Goldman Sachs’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-87,700
Closed -$593K – 6363
2024
Q4 		$593K Hold
87,700
– – ﹤0.01% 5146
2024
Q3 		$578K Buy
+87,700
New +$629K ﹤0.01% 4968

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs's RXRX Position: Q2 2026 in Review

Goldman Sachs reduced its Recursion Pharmaceuticals (RXRX) stake by 35% in Q2 2026, selling an estimated $7.15M and leaving 3,917,858 shares worth $14.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2949.

Goldman Sachs first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. The position peaked at $18.6M in Q1 2026. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Goldman Sachs held 3,917,858 shares of Recursion Pharmaceuticals worth $14.4M as of Q2 2026.
  • Goldman Sachs sold 2,147,803 Recursion Pharmaceuticals shares in Q2 2026, an estimated $7.15M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2949 holding.
  • Goldman Sachs first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Goldman Sachs's Recursion Pharmaceuticals position peaked at $18.6M in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.